Johnson & Johnson(JNJ-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low251.50
Day High255.56
Open:254.43
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
FILE PHOTO: The Johnson and Johnson loga is seen at an office building in Singapore January 17, 2018. REUTERS/Thomas White/File Photo
the globe and mail

J&J beats earnings estimates, plans orthopedics spinoff by mid-2027

Pharmaceutical sales rose 7.7%, driven by a 68% surge in Tremfya sales to US$2.4-billion
Zacks Investment Research
Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal
Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal
Zacks Investment Research
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
MarketBeat
MarketBeat Week in Review – 10/12 - 10/16
MarketBeat.com
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Omeros (OMER), Johnson & Johnson (JNJ)
Tipranks
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Revolution Medicines (RVMD) and Viridian Therapeutics (VRDN)
Tipranks
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), United Therapeutics (UTHR) and Johnson & Johnson (JNJ)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Liquidia Technologies (LQDA)
Stock Target Advisor
U.S. Analyst Updates: October 14th, 2026
U.S. Analyst Updates: October 14th, 2026
Tipranks
Johnson & Johnson Earnings Call: Growth Amid Headwinds
Zacks Investment Research
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance?
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance?
Zacks Investment Research
JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges
JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges
MarketBeat
Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
MarketBeat.com
Zacks Investment Research
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
Zacks Investment Research
Small-Business Optimism Dips in September
Small-Business Optimism Dips in September
Zacks Investment Research
Mixed Pre-Markets Greet Fresh Q3 Earnings Reports
Mixed Pre-Markets Greet Fresh Q3 Earnings Reports
Tipranks
Stifel Nicolaus Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
Tipranks
Johnson & Johnson (JNJ) Receives a Rating Update from a Top Analyst
SYNDTGAM
Premarket: S&P 500, Dow futures muted after big bank earnings, chip slide weighs
Traders work on the floor of the New York Stock Exchange (NYSE) at the opening bell, in New York City on October 5, 2026.
Baystreet
Canadian Investors Enjoy Shortened Week

Profile

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Market data provided by Barchart. Exchange delay details and data provider terms here. Information may be delayed, is provided 'as is' and is solely for informational purposes, and not for trading, investment or advice.